# Veradermics, Inc: financial statements, quarterly

MANE · NYSE · CIK 1827635 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mane.md) · [Financials](/companies/mane/financials.md) · [Filings](/companies/mane/filings.md) · [Insiders](/companies/mane/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mane/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $m | [11.4](/filings/0001827635-26-000019.md) | [14.3](/filings/0001827635-26-000030.md) | [20.9](/filings/0001827635-26-000019.md) | [18.6](/filings/0001827635-26-000030.md) |
| Operating income | $m | [(12.9)](/filings/0001827635-26-000019.md) | [(16.1)](/filings/0001827635-26-000030.md) | [(29.9)](/filings/0001827635-26-000019.md) | [(29.6)](/filings/0001827635-26-000030.md) |
| Income tax | $m | [0.0](/filings/0001827635-26-000019.md) | [0.0](/filings/0001827635-26-000030.md) | [0.0](/filings/0001827635-26-000019.md) | [0.0](/filings/0001827635-26-000030.md) |
| Net income | $m | [(12.4)](/filings/0001827635-26-000030.md) | [(15.6)](/filings/0001827635-26-000030.md) | [(27.2)](/filings/0001827635-26-000030.md) | [(23.5)](/filings/0001827635-26-000030.md) |
| Diluted EPS | $ per share | [(19.79)](/filings/0001827635-26-000019.md) | [(24.19)](/filings/0001827635-26-000030.md) | [(1.32)](/filings/0001827635-26-000019.md) | [(0.58)](/filings/0001827635-26-000030.md) |
| Basic EPS | $ per share | [(19.79)](/filings/0001827635-26-000019.md) | [(24.19)](/filings/0001827635-26-000030.md) | [(1.32)](/filings/0001827635-26-000019.md) | [(0.58)](/filings/0001827635-26-000030.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [53.1](/filings/0001827635-26-000013.md) | not reported | not reported | [21.8](/filings/0001827635-26-000030.md) | [168](/filings/0001827635-26-000019.md) | [319](/filings/0001827635-26-000030.md) |
| Current assets | $m | not reported | [55.5](/filings/0001827635-26-000013.md) | not reported | not reported | [152](/filings/0001827635-26-000030.md) | [397](/filings/0001827635-26-000019.md) | [825](/filings/0001827635-26-000030.md) |
| Total assets | $m | not reported | [55.5](/filings/0001827635-26-000013.md) | not reported | not reported | [153](/filings/0001827635-26-000030.md) | [397](/filings/0001827635-26-000019.md) | [826](/filings/0001827635-26-000030.md) |
| Current liabilities | $m | not reported | [4.7](/filings/0001827635-26-000013.md) | not reported | not reported | [9.2](/filings/0001827635-26-000030.md) | [6.7](/filings/0001827635-26-000019.md) | [11.7](/filings/0001827635-26-000030.md) |
| Total liabilities | $m | not reported | [4.7](/filings/0001827635-26-000013.md) | not reported | not reported | [9.2](/filings/0001827635-26-000030.md) | [6.7](/filings/0001827635-26-000019.md) | [12.1](/filings/0001827635-26-000030.md) |
| Shareholders' equity | $m | [(22.2)](/filings/0001827635-26-000013.md) | [(48.5)](/filings/0001827635-26-000030.md) | [(60.7)](/filings/0001827635-26-000030.md) | [(76.1)](/filings/0001827635-26-000030.md) | [(121)](/filings/0001827635-26-000030.md) | [391](/filings/0001827635-26-000030.md) | [814](/filings/0001827635-26-000030.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.3)](/filings/0001827635-26-000019.md) | [(15.6) d](/filings/0001827635-26-000030.md) | [(21.2)](/filings/0001827635-26-000019.md) | [(14.5) d](/filings/0001827635-26-000030.md) |
| Capital expenditure | $m | [0.0](/filings/0001827635-26-000019.md) | [0.0 d](/filings/0001827635-26-000030.md) | [0.0](/filings/0001827635-26-000019.md) | [0.0 d](/filings/0001827635-26-000030.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.7](/filings/0001827635-26-000019.md) | [0.7](/filings/0001827635-26-000030.md) | [22.7](/filings/0001827635-26-000019.md) | [40.4](/filings/0001827635-26-000030.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 41,780,136 at 2026-08-06, from the cover of the [10-Q filed 2026-08-11](/filings/0001827635-26-000030.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.